4T1/IL-2/GM-CSF vaccine - OncBioMune Pharmaceuticals

Drug Profile

4T1/IL-2/GM-CSF vaccine - OncBioMune Pharmaceuticals

Alternative Names: 4T1 whole cell vaccine - OncBioMune Pharmaceuticals; Ovcavax

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncBioMune Pharmaceuticals
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Ovarian cancer

Most Recent Events

  • 17 Oct 2017 OvcaVax plans a clinical trial for ovarian cancer in USA
  • 22 May 2017 Preclinical trials in Ovarian cancer in USA (unspecified route) (OncBioMune Pharmaceuticals pipeline, May 2017)
  • 01 Apr 2017 Preclinical trials in Breast cancer in USA (Intraperitoneal) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top